Option chain shows key data for Qualigen Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Qualigen Therapeutics.

Qualigen Therapeutics (NASDAQ:QLGN) Stock, Option Chain

Qualigen Therapeutics

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Tesla's Gross Margin Shows Worst Is Behind, Creating A 'Goldilocks' Scenario For Bulls, Says Dan Ives — Elon Musk-Led EV Giant Surges Over 12% In After-Hours Trading

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CARR

CCTG

CNSP

DBVT

GORO

ICLR

LRHC

MNDR

ORKT

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SDRL

SVRE

TSLA

VEEE

ZPTA

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Gold-image

Earnings

Equities

Eurozone

Commodities

APLD

CHPT

EAST

HOTH

NSSC

SAIC

Gold Moves Higher; Science Applications International Posts Upbeat Earnings

Crude-oil-4-logo

SGLY

SIFY

Dow Tumbles 1%; US Crude Oil Stocks Fall

Qualigen Therapeutics Inc

Press Releases

Qualigen Therapeutics, Inc. Announces management changes.

Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement

Qualigen to participate in next funding round for NanoSynex

Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

AKTS

CBDW

MRZM

RJDG

Aditxt

Alzamend Neuro

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

NuCana

Oragenics

Onconetix

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Qualigen Therapeutics, Inc.,

Comments

Qualigen Therapeutics

Qualigen Therapeutics (QLGN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell